# Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

> **NCT06484985** · PHASE1 · RECRUITING · sponsor: **Axter Therapeutics (Beijing) Co., Ltd** · enrollment: 78 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** AXT-1003

## Key facts

- **NCT ID:** NCT06484985
- **Lead sponsor:** Axter Therapeutics (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06484985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06484985, "Study of AXT-1003 in Subjects With Advanced Malignant Tumors.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06484985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*